ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elacestrant

Also written as “Elacestrant”, “RAD1901” and “Elacestrant dihydrochloride”.

Its studies are mostly in Breast Neoplasms · Hot Flashes, led by 3 companies.

Drug pageElacestrant: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 3, 201812 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Groupits history only95 open or runningphase 3since Dec 3, 2018Dec 31, 2014Nov 2026phase 2 · NCT05596409
Radius Pharmaceuticals20 open or runningphase 2since Mar 6, 2009Mar 6, 2009none ahead
Criteriumits history only10 open or runningphase 2since Dec 30, 2020Dec 30, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Radius Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2009First study: phase 2 study in Hot FlashesFirst studyNCT00875420 · 100 enrolled · United States
  2. Jan 8, 2016Phase 2 study in Hot FlashesNCT02653417 · 139 enrolled · United States
  3. Jun 9, 2016Named elacestrantINNProposed as its International Nonproprietary Name in WHO's List 115 · before, RAD1901

TargetBeta

ESR1 →read by rule
“An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity”NCIt, by rule
“Estrogen receptor alpha degrader; Estrogen receptor alpha degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 2 Radius Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02653417Hot Flashes · United States2TerminatedDec 12, 2016139
NCT00875420Hot Flashes · United States2CompletedJan 2010100

How it is read

Names in the registry

  • “Elacestrant”, 8 entries
  • “RAD1901”, 6 entries
  • “Elacestrant dihydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.